Biosimilars Market by Product (Recombinant Glycosylated Proteins (Monoclonal Antibodies (Rituximab, Adalimumab, and Infliximab), Erythropoietin, and Follitropin), Recombinant Non-Glycosylated Proteins (Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Hormone and Interferon (Interferon-Alpha and Interferon-Beta)), Recombinant Peptides (Glucagon and Calcitonin)), Type of Manufacturing (In-house Manufacturing, and Contract Manufacturing), Disease (Chronic Disease , Oncology, Autoimmune Disease, Blood disorders, Infectious Diseases, and Growth Hormone Deficiency) - Global Forecast to 2030

Report ID : 67  |  Published Date : Apr 2019  |  Pages : 150  |  Region : Global  |  Report Code : PH-2




Biosimilars Market Overview and Introduction

The global Biosimilars market was estimated  to be over US$ 4,500 Mn in 2018. It is anticipated to grow at a double digit CAGR from 2019 to 2030.

Biosimilars are bio-medical products that are identical copies of an original pharmaceutical drug, which has been manufactured by a different manufacturing company. Biosimilars are manufactured once the patent of the original product expires. Unlike generic drugs, biosimilars exhibit high molecular complexity and are sensitive to alterations in the processes of manufacturing. These drugs are similar to reference products, in terms of purity, safety and potency.  

The global biosimilars market is driven by cost effectiveness of drug due to which there is a increase demand of biosimilar drugs. Moreover, diverse applications of biosimilars for treatment of several chronic ailments, namely cancer and diabetes is anticipated to further contribute significantly to growing demand of this products in the coming years.  Furthermore the collaboration are in a strategic manner which result in enhanced productivity and clinical trials. However, availability of affordable generic drugs, and complexity involved in the process of manufacturing are likely to restrain the market to a certain extent.

Biosimilars Market by Product

On the basis of product, the biosimilars market can be segmented into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides. The segment of recombinant glycosylated proteins can be further segmented into monoclonal antibodies, erythropoietin, and follitropin. The monoclonal antibodies can be segmented into rituximab, adalimumab, and infliximab. The segment of recombinant non-glycosylated proteins can be classified into insulin, granulocyte colony stimulating factor, recombinant human growth hormone and interferon. The interferon can be further bifurcated into interferon-alpha and interferon-beta. Finally, the segment of recombinant peptides can be segmented into glucagon and calcitonin. The recombinant non-glycosylated proteins segment accounted for the largest market share in the global biosimilars market, owing to its wide range of therapeutic applications

Biosimilars Market by Type of Manufacturing

On the basis of type of manufacturing, the market can be segmented into in-house manufacturing and contract manufacturing. In terms of market share, the segment of in-house manufacturing accounted for the largest share, as in-house manufacturing reduces costs associated with shipping, delivery and thereby lowering the overall cost of manufacturing.  

Biosimilars Market by Diseases

Similarly, in terms of diseases the biosimilars market can be segmented into chronic disease, oncology, autoimmune disease, blood disorders, infectious diseases, growth hormone deficiency and other diseases. The blood disorder segment accounted for the largest share of the market, owing to low cost of biosimilars as compared to biologics, and rising incidence of blood disorders worldwide among others.

Biosimilars Market by Regions 

The global biosimilars market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). Europe dominated the market, followed by North America and Asia Pacific. Asia Pacific is expected to dominate the global market in the forecast period. Factors such as the patent expiry of launch of new biosimilars, biologic products, rising incidence of chronic disorders, and emergence of new market players are anticipated to drive market growth in this region  

Biosimilars Market Prominent Players

The prominent players in the global biosimilars market are Pfizer, Sandoz International, Teva Pharmaceuticals, Amgen, Biocon, Dr. Reddy’s Laboratories, Celltrion, Samsung Biologics, Stada Arzneimittel AG, and Mylan

Table of Contents

  1. INTRODUCTION
    1. Market Definition
    2. Market Ecosystem
      1. Market Classification
      2. Geographic Scope
      3. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecasted Years – 2019 to 2030
    3. Currency Used
  2. RESEARCH METHODOLOGY
    1. Research Framework
    2. Data Collection Technique
    3. Data Sources
      1. Secondary Sources
      2. Primary Sources
    4. Market Estimation Methodology
      1. Bottoms Up Approach
      2. Top Down Approach
    5. Data Validation and Triangulation
      1. Market Forecasting Model
      2. Limitations/Assumptions of the Study
  3. ABSTRACT OF THE STUDY
  4. MARKET DYNAMICS ASSESMENT
    1. Overview
    2. Drivers
    3. Barriers/Challenges
    4. Opportunities
  5. UNIQUE SELLING PROPOSITIONS (USPs)
    1. Regulatory Landscape Assessment
    2. Pipeline  Assessment
    3. Epidemiological Assessment: Oncology
  6. GLOBAL BIOSIMILARS MARKET- ANALYSIS & FORECAST, BY PRODUCT
    1. Recombinant Glycosylated Proteins
      1. Monoclonal Antibodies
        1. Rituximab
        2. Adalimumab
        3. Infliximab
        4. Other Monoclonal Antibodies
      2. Erythropoietin
      3. Follitropin
    2. Recombinant Non-glycosylated Proteins
      1. Insulin
      2. Granulocyte Colony Stimulating Factor
      3. Recombinant Human Growth Hormone
      4. Interferons
        1. Interferon-Alpha
        2. Interferon-Beta
    3. Recombinant Peptide
      1. Glucagon
      2. Calcitonin
  7. GLOBAL BIOSIMILARS MARKET - ANALYSIS & FORECAST, BY TYPE OF MANUFACTURING
    1. Contract  Manufacturing
    2. In- house Manufacturing
  8. GLOBAL BIOSIMILARS MARKET - ANALYSIS & FORECAST, BY DISEASE
    1. Chronic Disease
    2. Oncology
    3. Autoimmune Disease
    4. Blood disorders
    5. Infectious Diseases
    6. Growth Hormone Deficiency
    7. Other Disease
  9. GLOBAL BIOSIMILARS MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Biosimilars Market
      1. North America, By Country
        1.  US
        2.  Canada
      2. North America Analysis & Forecast, By Product
      3. North America Analysis & Forecast, By Type of Manufacturing
      4. North America Analysis & Forecast, By Diseases
    2. Europe Biosimilars Market
      1. Europ, By Country/Region
        1. Germany
        2. U.K
        3. France
        4. Rest of Europe (ROE)
      2. Europe Analysis & Forecast, By Product
      3. Europe Analysis & Forecast, By Type of Manufacturing
      4. Europe Analysis & Forecast, By Diseases
    3. Asia Pacific Biosimilars Market
      1. Asia Pacific, By Country/Region
        1. China
        2. Japan
        3. India
        4. Rest of Asia Pacific (RoAPAC)
      2. Asia Pacific Analysis & Forecast, By Product
      3. Asia Pacific Analysis & Forecast, By Type of Manufacturing
      4. Asia Pacific Analysis & Forecast, By Diseases
    4. Rest of the World (ROW) Biosimilars Market
      1. Rest of the World, By Country/ Region
        1. Latin America
        2. Middle East & Africa
      2. Rest of the World Analysis & Forecast, By Product
      3. Rest of the World Analysis & Forecast, By Type of Manufacturing
      4. Rest of the World Analysis & Forecast, By Diseases
  10. COMPETETIVE LANDSCAPE
    1. Market Share Analysis (2018)
    2. Key Strategies Assessment
      1. New Product Launches
      2. Merger & Acquisitions
      3. Agreements, Collaborations, & Partnerships
      4. Expansions
      5. Other Strategies
  11. COMPANY PROFILES (Business Overview, Products Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*
    1.  Pfizer
    2. Sandoz
    3. Teva Pharmaceuticals
    4. Amgen
    5. Biocon
    6. Dr. Reddy’s Laboratories 
    7. Celltrion
    8. Samsung Biologics
    9. Stada Arzneimittel AG
    10. Mylan


*Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain